NIH experts describe influenza vaccines of the future

Nov 17, 2010

In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to address the limitations of currently available influenza vaccines and develop more efficient and reliable strategies to make vaccines to protect against seasonal as well as pandemic influenza.

Although licensed seasonal flu vaccines safely and effectively protect most people who receive them from illness and death, the degree of protection varies depending on how well the circulating virus strains and those in the vaccine match. A vaccine recipient's age and health status also can affect the effectiveness of .

The authors discuss the spectrum of ongoing research that may transform the field in decades to come. Efforts to grow the vaccine virus in cells rather than eggs are currently under way and there is consideration of the addition to influenza vaccine of immune-stimulating adjuvants to be used in certain groups of individuals. Other approaches under development include influenza vaccines based on recombinant virus proteins, non-infectious virus-like particles, harmless vectors or influenza DNA. Also under intense study is the ultimate goal, a so-called universal that would provide protection against multiple strains of influenza, reducing the need for yearly flu shots while simultaneously protecting against novel flu viruses that may arise in the future.

To further protect vulnerable populations such as the elderly and those with underlying chronic diseases from seasonal influenza, as well as to quickly control the spread of potential viruses, influenza vaccine makers of the future must employ novel production technologies, the authors note.

Explore further: Physicians warned about counterfeit medical devices

More information: AS Fauci and L Lambert. Influenza vaccines for the future. New England Journal of Medicine DOI: 10.1056/ NEJMra1002842 (2010).

Provided by National Institutes of Health

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Universal flu vaccine holds promise

Apr 27, 2009

An influenza vaccine that protects against death and serious complications from different strains of flu is a little closer to reality, Saint Louis University vaccine researchers have found.

Recommended for you

EU regulator: Morning-after pill OK for all women

2 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

7 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

7 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

20 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 0